A method for isolating one or more blood products from an inter-alpha inhibitor protein (IαIp)-depleted blood product material, comprising: (a) chromatographically depleting at least about 80% of IαIp from a blood product material selected from the group consisting of whole plasma, cryo-poor plasma, liquid plasma, fresh frozen plasma, FFP24, frozen plasma, FP24, thawed FFP, thawed FFP24, thawed FP, thawed FP24, source plasma, recovered plasma, solvent/detergent-treated plasma, platelet-rich plasma, platelet-poor plasma, serum, blood, and a diluted or concentrated preparation thereof to produce the IαIp-depleted blood product material, wherein the IαIp-depleted blood product material comprises three or more blood products is selected from IVIg, alpha-1 antitrypsin, C1-inhibitor, albumin, IgA, IgG, IgM, IgD, IgG, anti-D IgG, hepatitis B IgG, measles IgG, rabies IgG, tetanus IgG, Varicella Zoster IgG, fibrinogen (factor I), prothrombin (factor II), thrombin, anti-thrombin III, factor III, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, fibronectin, alpha-2 antiplasmin, urokinase, protein C, protein S, protein Z, protein Z-related protease inhibitor, plasminogen, tissue plasminogen activator, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, von Willebrand factor, factor H, prekallikrein, high-molecular-weight kininogen, and heparin cofactor II; and (b) chromatographically isolating one or more of the blood products from said IαIp-depleted blood product material by contacting said IαIp-depleted blood product material to a support such that one or more of said blood products is substantially retained on said support. (a) chromatographically depleting at least about 80% of IαIp from a blood product material selected from the group consisting of whole plasma, cryo-poor plasma, liquid plasma, fresh frozen plasma, FFP24, frozen plasma, FP24, thawed FFP, thawed FFP24, thawed FP, thawed FP24, source plasma, recovered plasma, solvent/detergent-treated plasma, platelet-rich plasma, platelet-poor plasma, serum, blood, and a diluted or concentrated preparation thereof to produce the IαIp-depleted blood product material, wherein the IαIp-depleted blood product material comprises three or more blood products is selected from IVIg, alpha-1 antitrypsin, C1-inhibitor, albumin, IgA, IgG, IgM, IgD, IgG, anti-D IgG, hepatitis B IgG, measles IgG, rabies IgG, tetanus IgG, Varicella Zoster IgG, fibrinogen (factor I), prothrombin (factor II), thrombin, anti-thrombin III, factor III, factor V, factor VII, factor VIII, factor IX, factor X, factor XI, factor XII, factor XIII, fibronectin, alpha-2 antiplasmin, urokinase, protein C, protein S, protein Z, protein Z-related protease inhibitor, plasminogen, tissue plasminogen activator, plasminogen activator inhibitor-1, plasminogen activator inhibitor-2, von Willebrand factor, factor H, prekallikrein, high-molecular-weight kininogen, and heparin cofactor II; and (b) chromatographically isolating one or more of the blood products from said IαIp-depleted blood product material by contacting said IαIp-depleted blood product material to a support such that one or more of said blood products is substantially retained on said support.